Novogen (NASDAQ:KZIA) Stock Rated “Outperform” in New Coverage at Leerink Partners

Leerink Partners initiated coverage on shares of Novogen (NASDAQ:KZIA) in a research report report published on Tuesday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $30.00 target price on the stock.

Other equities research analysts have also issued reports about the stock. BTIG Research restated a “buy” rating and issued a $40.00 price objective on shares of Novogen in a report on Thursday, September 10th. Canaccord Genuity Group began coverage on shares of Novogen in a research report on Thursday, August 13th. They set a “buy” rating and a $29.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research note on Thursday, October 15th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.86.

Novogen Trading Down 1.3%

Shares of Novogen stock opened at $8.07 on Tuesday. Novogen has a 52-week low of $4.86 and a 52-week high of $17.40. The company has a 50 day moving average of $10.87 and a 200 day moving average of $12.00.

About Novogen

Novogen Limited was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.

Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.

In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA.